US20110002962A1 - Immunogenic PcpA Polypeptides and Uses Thereof - Google Patents

Immunogenic PcpA Polypeptides and Uses Thereof Download PDF

Info

Publication number
US20110002962A1
US20110002962A1 US12/377,446 US37744607A US2011002962A1 US 20110002962 A1 US20110002962 A1 US 20110002962A1 US 37744607 A US37744607 A US 37744607A US 2011002962 A1 US2011002962 A1 US 2011002962A1
Authority
US
United States
Prior art keywords
seq
pcpa
immunogenic fragment
composition
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/377,446
Other languages
English (en)
Inventor
David E. Briles
Susan K. Hollingshead
Jeremy Yethon
Joe Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
UAB Research Foundation
Original Assignee
Sanofi Pasteur Ltd
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd, UAB Research Foundation filed Critical Sanofi Pasteur Ltd
Priority to US12/377,446 priority Critical patent/US20110002962A1/en
Assigned to SANOFI PASTEUR LTD. reassignment SANOFI PASTEUR LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YETHON, JEREMY, WANG, JOE
Assigned to SANOFI PASTEUR LTD. reassignment SANOFI PASTEUR LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YETHON, JEREMY, WANG, JOE
Assigned to THE UAB RESEARCH FOUNDATION reassignment THE UAB RESEARCH FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRILES, DAVID E., HOLLINGSHEAD, SUSAN K.
Publication of US20110002962A1 publication Critical patent/US20110002962A1/en
Assigned to THE UAB RESEARCH FOUNDATION reassignment THE UAB RESEARCH FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRILES, DAVID E., HOLLINGSHEAD, SUSAN K.
Assigned to SANOFI PASTEUR LTD. reassignment SANOFI PASTEUR LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YETHON, JEREMY, WANG, JOE
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF ALABAMA AT BIRMINGHAM
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF ALABAMA AT BIRMINGHAM
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF ALABAMA AT BIRMINGHAM
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Definitions

  • Streptococcus pneumoniae is a rather ubiquitous human pathogen, which can infect several organs including lungs, the central nervous system (CNS), the middle ear, and the nasal tract. Infection results in various symptoms such as bronchitis, pneumonia, meningitis, sinus infection, and sepsis. S. pneumoniae is a major cause of bacterial meningitis in humans and is associated with significant mortality and morbidity despite antibiotic treatment (Quagliarello et al., (1992) N. Eng. J. Med. 327: 864-872).
  • pneumococcal vaccines There are two currently available pneumococcal vaccines.
  • One is a vaccine for adults composed of 23 different capsular polysaccharides, which together represent the capsular types of about 90% of strains causing pneumococcal infection.
  • This vaccine is not immunogenic in children, an age group with high susceptibility to pneumococcal infection.
  • the vaccine In adults the vaccine has been shown to be about 60% efficacious against bacteremic pneumonia, but it is less efficacious in adults at higher risk of pneumococcal infection because of age or underlying medical conditions (Fedson, and Musher. 2004. “Pneumococcal Polysaccharide Vaccine,” pp. 529-588. In Vaccines . S. A. Plotkin and W. A.
  • the second available vaccine is a 7-valent conjugate vaccine that is efficacious against bacteremic pneumococcal infections in children less than 2 years of age. It has also demonstrated efficacy against pneumonia (Black et al., Pediatr. Infect. Dis. 21:810-5 (2002); Black et al., Arch. Pediatr 11 (7):843-53 (2004)).
  • the production of this vaccine is complicated because of the need to produce 7 different conjugates, which leads to the vaccine being expensive (about $200/child).
  • the vaccine does not do a good job of covering infections in the developing world where non-vaccine types of Streptococcus pneumoniae are very common (Di Fabio et al., Pediatr. Infect. Dis. J.
  • compositions and methods for eliciting an immune response against Streptococcus pneumoniae are described. More particularly, the present disclosure relates to immunogenic PcpA polypeptides, including fragments of PcpA and variants thereof, and nucleic acids that encode the polypeptides. The present disclosure further relates to methods of making and using the immunogenic polypeptides. These compositions and methods offer improved efficacy and efficiency and reduced cost as compared to presently available compositions and methods designed to reduce or prevent pneumococcal infection.
  • FIG. 1 shows PCR confirmation of pcpA.
  • Primer pair (BGP1 (SEQ ID NO:50) and BGP2 (SEQ ID NO:51)) were used to amplify the nucleic acid encoding the N-terminal portion of PcpA (including the LRR region).
  • FIG. 2 shows Western blot analysis of PcpA presence under low Mn2+ conditions.
  • Bacteria were cultured in low Mn2+ medium until mid-log phase and total cellular protein samples prepared. Samples were separated by SDS-PAGE, transferred to nitrocellulose and probe with a rPcpA polyclonal antiserum.
  • FIG. 3 shows that protection conferred by rPcpA immunization compared to adjuvant alone was statistically significant in a murine model of pneumonia.
  • FIG. 4 shows that protection conferred against other S. pneumoniae capsular serotypes by rPcpA immunization versus adjuvant alone was statistically significant in a murine model of pneumonia.
  • FIG. 5 shows the effect of pcpA inactivation on intranasal colonization of S. pneumoniae .
  • Mice were challenged intranasally with 10 6 CFUs of EF3030 or its derivative JEN18. Mice were sacrificed 7 days post-infection and bacterial counts determined from nasal washes. Horizontal line denotes median Log 10 CFUs/Nose.
  • FIG. 6 shows that protection conferred by rPcpA immunization versus adjuvant alone was statistically significant in a murine model of fatal sepsis.
  • FIG. 8 shows that protection was conferred by rPcpA mucosal immunization compared to adjuvant alone in a murine model of pneumonia.
  • FIG. 9 shows adherence of pcpA+ and pcpA ⁇ TIGR4 strains (TIGR4 and JEN11, respectively) to human lung epithelial cells.
  • A549 human lung epithelial cell monolayers were incubated for 150 minutes with 10 6 CFU of pcpA+ and pcpA ⁇ TIGR4 strains that had been grown under high manganese (High Mn 2+ ) or low manganese (Low Mn 2+ ) growth conditions.
  • FIG. 10 shows pcpA+ and pcpA ⁇ TIGR4 strains did not adhere to human nasal epithelial cells.
  • Detroit562 human nasal epithelial cell monolayers were incubated for 150 minutes with 10 6 CFU of pcpA+ and pcpA ⁇ TIGR4 strains that had been grown under high manganese (High Mn 2+ ) or low manganese (Low Mn 2+ ) growth conditions. The cells were then washed and lysed. Numbers of pneumococci in the lysate were determined by quantitative plating on blood agar plates. Log 10 CFU recovered refers to the number of pneumococci at the end of the experiment.
  • FIG. 11 shows inhibition of adherence of pneumococci to A549 cells by an antibody to PcpA.
  • A549 human lung epithelial cell monolayers were incubated with 10 6 CFU of pcpA+ and pcpA ⁇ TIGR4 strains grown in high manganese (High Mn 2+ ) or low manganese (Low Mn 2+ ) without antibody, with 1/100 dilution, or with 1/50 dilution of PcpA antibody. The cells were washed and lysed. Numbers of pneumococci in the lysate were determined by quantitative plating on blood agar plates.
  • FIG. 12 shows protection against sepsis using rabbit sera to PcpA.
  • Rabbit serum was prepared by immunizing a rabbit with 100 ⁇ g rPcpA in complete Freund's adjuvant followed two and four weeks later by 100 ⁇ g rPcpA in complete Freund's adjuvant.
  • Sera was collected two weeks after the final boost and was shown to contain antibody to PcpA by dot blot assay.
  • Pre-immune sera was also collected before the start of the immunizations. Mice were tested in groups of two for the ability of dilutions of the rabbit anti-sera to protect against fatal pneumococcal infection.
  • mice received 0.1 mL of 1/10, 1/100 or 1/1000 dilutions of the immune sera intraperitoneally one hour prior to i.v. challenge with TIGR4.
  • Two mice received 1/10 pre-immune (non-immune) rabbit serum and two mice received the diluent, PBS, only. Mice were observed for 500 hours or until time of death. The two mice receiving 1/10 immune sera lived throughout the experiment. All other mice died between 40 and 60 hours post challenge.
  • FIG. 13 shows protection against lung infection with PcpA and pneumolysin (Ply).
  • Mice were immunized three times with 5 ⁇ g of rPcpA, 5 ⁇ g of pneumolysin (Ply), or 5 ⁇ g of rPcpA plus 5 ⁇ g Ply. The first two injections were with alum and the third injection was with protein alone. The Ply used was wild-type Ply. Mice were anethesized with isoflurane (MinRAD, Buffalo, N.Y.) and challenged i.n. with 5 ⁇ 10 6 CFU of capsular type 19F strain EF3030 in 40 ⁇ L volume. This procedure results in lung infection and nasal colonization.
  • mice Seven days later mice were sacrificed and homogenized lungs were plated. The CFU observed indicated that immunization with either PcpA or Ply resulted in similar levels of protection. Mice immunized with PcpA and Ply resulted in over 100-fold more protection than control mice and 10 times more protection than Ply or PcpA alone.
  • FIG. 14 is a schematic showing the construction of the plasmid pJMS87 formed by ligation of the plasmid pET30a and a nucleic acid encoding a fragment of PcpA ( ⁇ SP ⁇ CBD PcpA from Streptococcus pneumoniae strain B6).
  • FIGS. 15A and 15B are graphical representations of the protection conferred by immunizing mice with the recombinant PcpA (rPcpA) of Example 8 (10 to 0.625 ⁇ g/dose) in a murine sepsis model. Mice were challenged intraperitoneally with 300 CFU of strain WUBM3.
  • FIG. 15A shows that rPcpA immunized mice at each dose were significantly protected when compared to the adjuvant control group (PBS) (Fisher Exact Test) over a period of time.
  • FIG. 15B shows the level of protection in each group at day 7 post challenge.
  • PBS adjuvant control group
  • FIG. 16 is a graphical representation of the protection conferred by immunization with the rPcpA of Example 8 in a mouse pneumonia model.
  • Groups 1 to 6 were immunized with placebo (Group 1), PspA (Group 2) or rPcpA (Groups 3 to 6).
  • Approximately 14 CBA/N mice per group were immunized at day 0 subcutaneously (s.c.) with a primary dose of immunogen.
  • a second immunization was performed at day 21 and a third immunization at day 43.
  • the mice were challenged intranasally with 5.6 ⁇ 10 6 CFU of S. pneumoniae strain EF3030. Five days post infection CFU were determined in homogenized lung tissue.
  • PcpA which was initially identified as a choline binding protein (CBP) of Streptococcus pneumoniae , differs from the CBP proteins PspA and PspC (Sanchez-Beato et al., FEMS Microbiol. Lett. 164:207-214 (1998)), and mutations in pcpA have been shown to cause (1) reduced virulence in the lung, in bacteremia, and in the nasopharynx of mice in competition models in which a mutant strain and a wild type strain are allowed to compete (Hava and Camilli, Mol. Microbiol.
  • CBP choline binding protein
  • Immunogenic polypeptides comprise the full-length PcpA amino acid sequence (in the presence or absence of the signal sequence), fragments thereof, and variants thereof.
  • Full-length PcpA includes GenBank Accession No. CAB04758 from Streptococcus pneumoniae strain B6, GenBank Accession No. NP — 346554 from S. pneumoniae strain TIGR4 and GenBank Accession No. NP — 359536 from S. pneumoniae strain R6.
  • immunogenic polypeptides of PcpA comprise one or more leucine rich regions (LRRs).
  • LRRs are present in naturally occurring PcpA or have about 60 to about 99% sequence identity, including, for example, 80%, 85%, 90% or 95% sequence identity to the naturally occurring LRRs.
  • LRRs in the mature PcpA protein i.e., the protein lacking the signal peptide
  • SEQ ID NOs: 1, 2, 41 or 45 can be found within SEQ ID NOs: 1, 2, 41 or 45.
  • an immunogenic polypeptide of PcpA optionally lacks the choline binding anchor sequence typically present in the naturally occurring mature PcpA protein.
  • the naturally occurring sequence of the choline binding anchor is SEQ ID NO:52 of the mature PcpA protein.
  • an immunogenic polypeptide comprises an N-terminal region of naturally occurring PcpA with one or more amino acid substitutions and about 60 to about 99% sequence identity or any identity in between, e.g., 80, 85, 90 and 95% identity, to the naturally occurring PcpA.
  • the N-terminal region may comprise the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 41 or 45, in the presence or absence of one or more conservative amino acid substitutions and in the presence or absence of the signal sequence.
  • the N-terminal region may comprise an amino acid sequence having about 60 to about 99% sequence identity (or any identity in between 80 to 99% identity) to SEQ ID NOs: 1, 2, 3, 4, 41 or 45.
  • Immunogenic fragments of SEQ ID NOs:1, 2, 3, 4, 41 or 45 comprise 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 and 191 amino acid residues of SEQ ID NOs: 1, 2, 3, 4, 41 or 45 or any number of amino acid residues between 5 and 191.
  • fragments include, by way of example, amino acids comprising LEKIEDRAFD (SEQ ID NO:5), FSELEEIELP (SEQ ID NO:6), ASLEYIGTSA (SEQ ID NO:7), FSFSQKLKKL (SEQ ID NO:8), TFSSSSKLEL (SEQ ID NO:9), ISHEAFANLS (SEQ ID NO:10), NLEKLTLPKS (SEQ ID NO:11), VKTLGSNLFR (SEQ ID NO:12), LTTSLNMLML (SEQ ID NO:13), LTTSLKHVDV (SEQ ID NO:14), RGMIVASVDG (SEQ ID NO:15), EEGNESFASVDG (SEQ ID NO:16), VSFQSKTQLI (SEQ ID NO:17), VLFSKDKTQLI (SEQ ID NO:18), YYPSQKNDES (SEQ ID NO:19), YKTPKETKEL (SEQ ID NO:20), ASYSFNKNSY (SEQ ID NO:
  • immunogenic polypeptides of PcpA lack the LRRs.
  • immunogenic polypeptides lacking the LRR include SEQ ID NO:29, SEQ ID NO:30, and SEQ ID NO:31 or any immunogenic fragment of either SEQ ID NOs:29, 30 or 31 comprising 5 or more amino acid residues.
  • SEQ ID NOs:30 and 31 comprise the residues C-terminal to the leucine-rich region of PcpA.
  • Variants of the immunogenic polypeptides described herein may comprise one or more conservative amino acid substitutions.
  • Variants of the immunogenic polypeptides include amino acid sequence having about 60 to about 99% sequence identity (or any identity in between 60 and 99% identity) to SEQ ID NOs:1 to 31, 41 and 45 or any fragment thereof. Variants are selected for their immunogenic capacity using methods taught herein.
  • the immunogenic polypeptides of PcpA described herein include fragments of PcpA and variants of such fragments.
  • Variants of PcpA fragments may comprise amino acid sequence modifications.
  • amino acid sequence modifications include substitutional, insertional or deletional changes. Substitutions, deletions, insertions or any combination thereof may be combined in a single variant so long as the variant is an immunogenic polypeptide.
  • Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues.
  • Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about from 2 to 6 residues are deleted at any one site within the protein molecule. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known and include, but are not limited to, M13 primer mutagenesis and PCR mutagenesis. Amino acid substitutions are typically of single residues but can occur at a number of different locations at once.
  • substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 1 and are referred to as conservative substitutions. However, others are well known to those of skill in the art.
  • Variants as used herein may also include naturally occurring pcpA alleles from alternate strains that exhibit polymorphisms at one or more sites within the homologous pcpA gene. Variants can be produced by conventional molecular biology techniques. The variants are described herein relative to sequence identity as compared to the naturally occurring pcpA. Those of skill in the art readily understand how to determine the sequence identity of two polypeptides or nucleic acids. For example, the sequence identity can be calculated after aligning the two sequences so that the identity is at its highest level. Alignments are dependent to some extent upon the use of the specific algorithm in alignment programs. This could include, for example, the local homology algorithm of Smith and Waterman Adv. Appl. Math.
  • the immunogenic polypeptides described herein can include one or more amino acid analogs or non-naturally occurring stereoisomers. These amino acid analogs and stereoisomers can readily be incorporated into polypeptide chains by charging tRNA molecules with the amino acid of choice and engineering genetic constructs that utilize, for example, amber codons, to insert the analog amino acid into a peptide chain in a site specific way (Thorson et al., Methods in Molec. Biol.
  • Immunogenic fragments can be produced that resemble peptides but which are not connected via a natural peptide linkage.
  • linkages for amino acids or amino acid analogs can include CH2NH—, —CH2S—, —CH2-CH2-, —CH ⁇ CH— (cis and trans), —COCH2-, —CH(OH)CH2-, and —CHH2SO— (These and others can be found in Spatola, A. F. “Peptide backbone modifications: A structure-activity analysis of peptides containing amide bond surrogates, conformational constraints, and related backbone modifications.” In Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins , pp. 267-357. Weinstein, B. editor, Marcel Dekker, New York, N.Y. (1983); Morley, Trends in Pharm. Sci.
  • Amino acid analogs and stereoisomers often have enhanced or desirable properties, such as, more economical production, greater chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), and others.
  • D-amino acids can be used to generate more stable peptides, because D amino acids are not recognized by naturally occurring peptidases.
  • Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type e.g., D-lysine in place of L-lysine
  • D-lysine in place of L-lysine
  • Cysteine residues can be used to cyclize or attach two or more peptides together. This can be beneficial to constrain peptides into particular conformations. (Rizo and Gierasch Ann. Rev. Biochem. 61:387 (1992), incorporated herein by reference).
  • compositions comprising an immunogenic polypeptide of PcpA and a pharmaceutically acceptable carrier are described herein.
  • the composition further comprises an adjuvant.
  • Compositions comprising the immunogenic polypeptide may contain combinations of other immunogenic polypeptides, including, for example, an immunogenic Staphylococcus polypeptide or immunogenic fragments of PspA, pneumolysin, or a combination thereof.
  • compositions described herein are suitable for administration to a mucosal surface.
  • the composition can be a nasal spray, a nebulizer solution, or an aerosol inhalant, for example.
  • the composition may be present in a container and the container may be a nasal sprayer, a nebulizer, or an inhaler.
  • pharmaceutically acceptable carrier a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the immunogenic fragment of PcpA, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
  • the carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.
  • Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy, 21 st Edition, David B. Troy, ed., Lippicott Williams & Wilkins (2005).
  • an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic.
  • the pharmaceutically-acceptable carriers include, but are not limited to, sterile water, saline, buffered solutions like Ringer's solution, and dextrose solution. The pH of the solution is generally from about 5 to about 8 or from about 7 to about 7.5.
  • Other carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the immunogenic PcpA polypeptides.
  • Matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered. Carriers are those suitable for administration of the PcpA immunogenic fragments to humans or other subjects.
  • compositions may include carriers, thickeners, diluents, buffers, preservatives, surface active agents, adjuvants, immunostimulants, in addition to the immunogenic polypeptide.
  • Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial agents, anti-inflammatory agents and anesthetics.
  • Adjuvants include metallic salts, such as aluminium salts, and are well known in the art as providing a safe excipient with adjuvant activity.
  • the mechanism of action of these adjuvants are thought to include the formation of an antigen depot such that antigen may stay at the site of injection for up to 3 weeks after administration, and also the formation of antigen/metallic salt complexes which are more easily taken up by antigen presenting cells.
  • other metallic salts have been used to adsorb antigens, including salts of zinc, calcium, cerium, chromium, iron, and berilium.
  • the hydroxide and phosphate salts of aluminium are the most common.
  • Formulations or compositions containing aluminium salts, antigen, and an additional immunostimulant are known in the art.
  • An example of an immunostimulant is 3-de-O-acylated monophosphoryl lipid A (3D-MPL).
  • the adjuvant and/or immunostimulant can be administered concomitantly with the polypeptide composition, immediately prior to, or after administration of the composition.
  • the composition further comprises the adjuvant.
  • Adjuvant formulations include, for example, an agent that targets mucosal inductive sites.
  • the adjuvant may optionally be selected from the group including, but not limited to, cytokines, chemokines, growth factors, angiogenic factors, apoptosis inhibitors, and combinations thereof.
  • the cytokine may be selected from the group including, but not limited to, interleukins including IL-1, IL-3, IL-2, IL-5, IL-6, IL-12, IL-15 and IL-18; transforming growth factor-beta (TGF- ⁇ ); granulocyte macrophage colony stimulating factor (GM-CSF); interferon-gamma (IFN- ⁇ ); or any other cytokine that has adjuvant activity.
  • TGF- ⁇ transforming growth factor-beta
  • GM-CSF granulocyte macrophage colony stimulating factor
  • IFN- ⁇ interferon-gamma
  • Portions of cytokines, or mutants or mimics of cytokines (or combinations thereof), having adjuvant activity or other biological activity can also be used in the compositions and methods of the present invention.
  • the chemokine may optionally be selected from a group including, but not limited to, Lymphotactin, RANTES, LARC, PARC, MDC, TAR C, SLC and FKN.
  • the apoptosis inhibitor may optionally be selected from the group including, but not limited to, inhibitors of caspase-8, and combinations thereof.
  • the angiogenic factor may optionally be selected from the group including, but not limited to, a basic fibroblast growth factor (FGF), a vascular endothelial growth factor (VEGF), a hyaluronan (HA) fragment, and combinations thereof.
  • FGF basic fibroblast growth factor
  • VEGF vascular endothelial growth factor
  • HA hyaluronan fragment
  • substantially non-toxic, biologically active adjuvants include hormones, enzymes, growth factors, or biologically active portions thereof.
  • hormones, enzymes, growth factors, or biologically active portions thereof can be of human, bovine, porcine, ovine, canine, feline, equine, or avian origin, for example, and can be tumor necrosis factor (TNF), prolactin, epidermal growth factor (EGF), granulocyte colony stimulating factor (GCSF), insulin-like growth factor (IGF-1), somatotropin (growth hormone) or insulin, or any other hormone or growth factor whose receptor is expressed on cells of the immune system.
  • TNF tumor necrosis factor
  • prolactin prolactin
  • EGF epidermal growth factor
  • GCSF granulocyte colony stimulating factor
  • IGF-1 insulin-like growth factor
  • growth hormone growth hormone
  • Adjuvants also include bacterial toxins, e.g., the cholera toxin (CT), the E. coli heat-labile toxin (LT), the Clostridium difficile toxin A and the pertussis toxin (PT), or combinations, subunits, toxoids, chimera, or mutants thereof.
  • CT cholera toxin
  • LT E. coli heat-labile toxin
  • PT pertussis toxin
  • a purified preparation of native cholera toxin subunit B (CTB) can be used. Fragments, homologs, derivatives, and fusions to any of these toxins are also suitable, provided that they retain adjuvant activity.
  • CTB native cholera toxin subunit B
  • Suitable mutants or variants of adjuvants are described, e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627 (Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PT mutant).
  • Additional LT mutants that can be used in the methods and compositions include, e.g., Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants.
  • adjuvants such as RH3-ligand; CpG-motif oligonucleotide; a bacterial monophosphoryl lipid A(MPLA) of, e.g., E. coli, Salmonella minnesota, Salmonella typhimurium , or Shigella exseri ; saponins (e.g., QS21), or polylactide glycolide (PLGA) microspheres, can also be used.
  • Possible other adjuvants are defensins and CpG motifs.
  • polypeptides described herein can be generated using standard molecular biology techniques and expression systems. (See, for example, Molecular Cloning: A Laboratory Manual, Third Edition by Sambrook et al., Cold Spring Harbor Press, 2001).
  • a fragment of the pcpA gene that encodes an immunogenic polypeptide may be isolated and the polynucleotide encoding the immunogenic polypeptide may be cloned into any commercially available expression vector (such as pBR322 and pUC vectors (New England Biolabs, Inc., Ipswich, Mass.)) or expression/purification vectors (such as GST fusion vectors (Pfizer, Inc., Piscataway, N.J.)) and then expressed in a suitable prokaryotic, viral or eukaryotic host. Purification may then be achieved by conventional means or, in the case of a commercial expression/purification system, in accordance with a manufacturer's instructions.
  • any commercially available expression vector such as pBR322 and pUC vectors (New England Biolabs, Inc., Ipswich, Mass.)
  • expression/purification vectors such as GST fusion vectors (Pfizer, Inc., Piscataway, N.J.)
  • nucleic acids comprising a sequence that encodes any one of SEQ ID NOs:1 to 31, 41 and 45.
  • a nucleic acid comprising SEQ ID NOs:32, 33 and 47, which encode full length PcpA proteins or fragments thereof.
  • SEQ ID NOs:1 and 2 or fragments thereof are described, including SEQ ID NO:34 and SEQ ID NO:35, respectively, or degenerate variants or fragments thereof.
  • Nucleic acids that encode SEQ ID NOs:3 and 4 or fragments thereof include, but are not limited to, SEQ ID NOs:36 and 37, respectively, or degenerate variants or fragments thereof.
  • Nucleic acids that encode SEQ ID NO:41 or fragments thereof are described, including SEQ ID NO:42 or degenerate variants or fragments thereof.
  • SEQ ID NO:45 Nucleic acids that encode SEQ ID NO:45 or fragments thereof are described, including SEQ ID NO:46 or degenerate variants or fragments thereof.
  • Exemplary nucleic acids that encode SEQ ID NO:29 or fragments thereof include SEQ ID NO:38 or degenerate variants or fragments thereof.
  • nucleic acid comprising any one of the sequences designated as SEQ ID NOs:32 to 38, 42, 46 and 47 or degenerate variants thereof.
  • isolated nucleic acids comprising a sequence that hybridizes under highly stringent conditions to all or any portion of a hybridization probe having a nucleotide sequence that comprises SEQ ID NOs:32 to 38, 42, 46 and 47 or the complement of SEQ ID NOs:32 to 38, 42, 46 and 47 or any fragment of the sequence or complement thereof.
  • the hybridizing portion of the hybridizing nucleic acid is typically at least 15 (e.g., 15, 20, 25, 30, 40, or more) nucleotides in length.
  • the hybridizing portion is at least 80% (e.g., 85%, 90% or 95%) identical to the a portion of the sequence to which it hybridizes.
  • Hybridizing nucleic acids are useful, for example, as cloning probes, primers (e.g., PCR primer), or a diagnostic probe.
  • Nucleic acid duplex or hybrid stability is expressed as the melting temperature or Tm, which is the temperature at which a probe dissociates from a target DNA. This melting temperature is used to define the required stringency conditions. If sequences are identified that are related and substantially identical to the probe, rather than identical, then it is useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (e.g., SSC or SSPE). Assuming that a 1% mismatching results in a 1° C.
  • salt e.g., SSC or SSPE
  • the temperature of the final wash in the hybridization reaction is reduced accordingly (for example, if sequences having more than 95% identity are sought, the final wash temperature is decreased by 5° C.).
  • the change in Tm can be between 0.5 and 1.5° C. per 1% mismatch.
  • Highly stringent conditions involve hybridizing at 68° C. in 5 ⁇ SSC/5 ⁇ Denhardt's solution/1.0% SDS, and washing in 0.2 ⁇ SSC/0.1% SDS at room temperature.
  • Moderately stringent conditions include washing in 3 ⁇ SSC at 42° C. Salt concentrations and temperatures can be varied to achieve the optimal level of identity between the probe and the target nucleic acid. Additional guidance regarding such conditions is readily available in the art, for example, in Molecular Cloning: A laboratory Manual, Third Edition by Sambrook et al., Cold Spring Harbor Press, 2001.
  • nucleic acids that can encode the aforementioned peptide sequences, variants and fragments thereof are disclosed. This would include all degenerate sequences related to a specific protein sequence, i.e., all nucleic acids having a sequence that encodes one particular protein sequence as well as all nucleic acids, including degenerate nucleic acids, encoding the disclosed variants and derivatives of the protein sequences.
  • each particular nucleic acid sequence may not be written out herein, it is understood that each and every sequence is in fact disclosed and described herein through the disclosed protein sequence.
  • vectors comprising the nucleic acids described herein.
  • a vector that comprises a nucleic acid that encodes an immunogenic polypeptide (e.g., SEQ ID NOs:1 to 31, 41 or 45 or fragments or variants thereof).
  • the vector can comprise any of the nucleic acid sequences SEQ ID NOs:32 to 38, 42 and 47 or degenerate variants or fragments thereof.
  • the nucleic acid of the vector is operably linked to an expression control sequence (e.g., a promoter or enhancer or both).
  • Suitable expression vectors are well known to those of skill in the art and commercially available from a variety of sources such as Novagen, Inc., Madison, Wis.; Invitrogen Corporation, Carlsbad, Calif.; and Promega Corporation, Madison, Wis.
  • a cultured cell comprising the vector is also provided.
  • the cultured cell can be a cultured cell transfected with the vector or a progeny of the cell, wherein the cell expresses the immunogenic polypeptide.
  • Suitable cell lines are known to those of skill in the art and are commercially available, for example, through the American Type Culture Collection (ATCC).
  • the transfected cells can be used in a method of producing an immunogenic polypeptide.
  • the method comprises culturing a cell comprising the vector under conditions that allow expression of the immunogenic polypeptide, optionally under the control of an expression sequence.
  • the immunogenic polypeptide can be isolated from the cell or the culture medium using standard protein purification methods.
  • the immunogenic polypeptides can be made using standard enzymatic cleavage of larger polypeptides or proteins or can be generated by linking two or more peptides or polypeptides together by protein chemistry techniques.
  • peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (tert-butyloxycarbonyl) chemistry. (Applied Biosystems, Inc., Foster City, Calif.).
  • the immunogenic polypeptides and compositions comprising one or more polypeptides may be used to generate antibodies.
  • a method of generating antibodies specific to PcpA in a subject comprises administering to the subject a immunogenic PcpA fragment described herein.
  • antibodies that bind the PcpA polypeptides as well as antibody fragments that bind the PcpA polypeptides are also provided herein.
  • Antibodies may be polyclonal or monoclonal, may be fully human or humanized, and include naturally occurring antibodies and single-chain antibodies. Antibodies can be made in vivo by administering to a subject an immunogenic PcpA polypeptide. Antibody production includes making monoclonal antibodies using hybridoma methods. Hybridoma methods are well known in the art and are described by Kohler and Milstein, Nature, 256:495 (1975) and Harlow and Lane. Antibodies, A Laboratory Manual . Cold Spring Harbor Publications, New York, (1988), which are incorporated by reference in their entirety for the methods described therein.
  • a single chain antibody is created by fusing together the variable domains of the heavy and light chains using a short peptide linker, thereby reconstituting an antigen binding site on a single molecule.
  • Single-chain antibody variable fragments scFvs in which the C-terminus of one variable domain is tethered to the N-terminus of the other variable domain via a 15 to 25 amino acid peptide or linker have been developed without significantly disrupting antigen binding or specificity of the binding.
  • the linker is chosen to permit the heavy chain and light chain to bind together in their proper conformational orientation. See, for example, Huston, J. S., et al., Methods in Enzym. 203:46-121 (1991), which is incorporated herein by reference for its material regarding linkers.
  • Fully human and humanized antibodies to the PcpA polypeptides may be used in the methods described herein.
  • Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • CDR complementary determining region
  • donor antibody such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • Transgenic animals e.g., mice
  • mice that are capable, upon immunization, of producing a full repertoire of human antibodies (i.e., fully human antibodies) may be employed.
  • J(H) antibody heavy chain joining region
  • transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice results in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits et al., PNAS USA, 90:2551-255 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Year in Immuno., 7:33 (1993)).
  • Human antibodies can also be produced in phage display libraries (Hoogenboom et al., J. Mol.
  • Antibody fragment as used herein includes F(ab′)2, Fab′, and Fab fragments, including hybrid fragments. Such fragments of the antibodies retain the ability to bind a specific PcpA polypeptide.
  • Methods can be used to construct (ab) expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F(ab) fragments with the desired specificity for a PcpA polypeptide.
  • Antibody fragments that contain the idiotypes to the polypeptide may be produced by techniques known in the art including, but not limited to: (i) an F(ab′)2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F(ab′)2 fragment; (iii) an F(ab) fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F(v) fragments.
  • Described herein is a method of reducing the risk of a pneumococcal infection in a subject comprising administering to the subject the immunogenic fragment of PcpA or a composition thereof.
  • Pneumococcal infections include, for example, meningitis, otitis media, pneumonia, sepsis, or hemolytic uremia. Thus, the risk of any one or more of these infections are reduced by the methods described herein.
  • the method can further comprise the step of administering a second immunogenic fragment.
  • the second immunogenic fragment can be from PspA, pneumolysin, or a combination thereof.
  • the second immunogenic fragment can be administered at the same time, before or after the immunogenic fragment of PcpA.
  • compositions comprising a PcpA polypeptide or fragments thereof may be administered orally, parenterally (e.g., intravenously), intramuscularly, intraperitoneally, transdermally or topically, including intranasal administration or administration to any part of the respiratory system.
  • parenterally e.g., intravenously
  • intramuscularly e.g., intraperitoneally
  • transdermally e.g., transdermally or topically
  • administration to the respiratory system means delivery of the compositions into the nose and nasal passages through one or both of the nares or through the mouth, including delivery by a spraying mechanism or droplet mechanism, through aerosolization or intubation.
  • compositions and PcpA polypeptides or fragments required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the polypeptide used, and its mode of administration. Thus, it is not possible to specify an exact amount for every composition. However, an appropriate amount can be determined by one of ordinary skill in the art given the description herein. Furthermore, multiple doses of the PcpA polypeptide or fragment may be used including, for example, in a prime and boost regimen.
  • compositions comprising PcpA or immunogenic fragments can optionally comprise a second immunogenic fragment of PcpA, PspA, or pneumolysin, or a combination thereof.
  • Combinations may be administered either concomitantly (e.g., as an admixture), separately but simultaneously (e.g., via separate intravenous lines into the same subject), or sequentially (e.g., one of the compounds or agents is given first followed by the second).
  • combination is used to refer to either concomitant, simultaneous, or sequential administration of two or more agents.
  • a subject is meant an individual.
  • the subject can include domesticated animals, such as cats and dogs, livestock (e.g., cattle, horses, pigs, sheep, and goats), laboratory animals (e.g., mice, rabbits, rats, guinea pigs) and birds.
  • livestock e.g., cattle, horses, pigs, sheep, and goats
  • laboratory animals e.g., mice, rabbits, rats, guinea pigs
  • the subject is a mammal such as a primate or a human.
  • composition can comprise a combination means that the composition may comprise a combination of different molecules or may not include a combination such that the description includes both the combination and the absence of the combination (i.e., individual members of the combination).
  • Ranges may be expressed herein as from about one particular value, and/or to about another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent about, it will be understood that the particular value forms another aspect. It will be Further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
  • prevent, preventing, and prevention are used herein in connection with a given treatment for a given condition (e.g., preventing pneumococcal infection), they mean that the treated patient either does not develop a clinically observable level of the condition at all, or develops it more slowly and/or to a lesser degree than he/she would have absent the treatment. These terms are not limited solely to a situation in which the patient experiences no aspect of the condition whatsoever.
  • a treatment will be said to have prevented the condition if it is given during exposure of a patient to a stimulus that would have been expected to produce a given manifestation of the condition, and results in the patient's experiencing fewer and/or milder symptoms of the condition than otherwise expected.
  • a treatment can prevent infection by resulting in the patient's displaying only mild overt symptoms of the infection; it does not imply that there must have been no penetration of any cell by the infecting microorganism.
  • reduce, reducing, and reduction as used herein in connection with the risk of infection with a given treatment refers to a subject developing an infection more slowly or to a lesser degree as compared to a control or basal level of developing an infection in the absence of a treatment (e.g., administration of an immunogenic polypeptide).
  • a reduction in the risk of infection may result the patient's displaying only mild overt symptoms of the infection or delayed symptoms of infection; it does not imply that there must have been no penetration of any cell by the infecting microorganism.
  • S. pneumoniae strains TIGR4 and EF3030, and their derivatives were used in this study. Pneumococci were grown at 37° C. in Todd-Hewitt broth with 0.5% yeast extract (THY) or on blood agar plates unless otherwise indicated. When appropriate, erythromycin was added to the medium at a concentration of 0.3 ⁇ g/ml. Clinical isolates of S. pneumoniae (Table 2) and isolates of major clonal groups (Table 3) were used.
  • Plasmids were maintained in Escherichia coli TOP10 cells (Invitrogen, Carlsbad, Calif.) grown in Luria-Bertani (LB) broth or LB plates with 1.5% agar. Ampicillin (50 ⁇ g/ml) for pCR2.1, pCR4 and pET-20b-based plasmids or erythromycin (400 ⁇ g/ml) for pJY4164-based plasmids was added to the growth medium.
  • THY medium was used for growth of bacteria in high manganese medium. For growth in low manganese conditions, a manganese depleted form of THY was prepared. THY medium was prepared according to the manufacturer's directions, with Chelex-100 (2% w/v) (Sigma Aldrich, St. Louis, Mo.) added prior to autoclaving. After autoclaving, the THY/Chelex mixture was stirred overnight at room temperature, followed by filter sterilization. ZnCl 2 , MgCl 2 , CaCl 2 , and FeSO 4 were added to concentrations of 1 mM each, and MnSO 4 was add to a concentration of 0.1 ⁇ M prior to use. Growth was monitored by optical density at 600 nm.
  • Reactions were carried out for 30 cycles in a total volume of 50 ⁇ l in a cocktail containing 3.0 mM MgCl 2 , 125 ⁇ M dNTPs, 50 picomole of each primer, and 2.5 units of Taq DNA Polymerase.
  • the cycle was 94° C., 1 min.; 55° C., 1 min; 72° C., 5 minutes.
  • This amplified gene fragment was initially cloned into pTOPO4 (Invitrogen, Inc., Carlsbad, Calif.) by a T-tailed method forming plasmid pLMG.
  • This fragment was cloned into pCR4 with the TOPO TA cloning kit (Invitrogen, Carlsbad, Calif.). Purified plasmids were screened by endonuclease digestion with BamHI and XhoI (Promega, Madison, Wis.). Agarose gel electrophoresis, PCR analysis, and DNA sequencing were all used to confirm insertion of the pcpA fragment in the resulting plasmid, pDG-1. The insert from pDG-1 was subcloned into the pET-20b expression vector (Novagen, Madison, Wis.). The resulting plasmid, pJM-1, was transformed into the E.
  • Anti-PcpA polyclonal antibody production Purified rPcpA was used to immunize a New Zealand White Rabbit (Myrtle's Rabbity, Thompson Station, Tenn.) rabbit subcutaneously to obtain anti-PcpA polyclonal serum.
  • the rabbit was injected subcutaneously with 100 ⁇ g of rPcpA in 1 ml of Freund's complete adjuvant, 2 ml total volume.
  • a second boost, with 100 ⁇ g of rPcpA in Freund's incomplete adjuvant was given 2 weeks later and a third boost of 100 ⁇ g of PcpA in Freund's incomplete adjuvant was given 2 weeks after the second boost.
  • Two weeks following the final boost the rabbit was bled by cardiac puncture, under anesthesia.
  • the blood was allowed to clot, and serum was obtained by centrifugation and stored at ⁇ 80° C.
  • PCR confirmation of pcpA in S. pneumoniae strains The presence or absence of pcpA in various S. pneumoniae strains was checked using PCR primer pair BGP-1 and BGP-2. The primer pair was designed to amplify a 1416 bp N-terminal fragment of pcpA in strain TIGR4. The PCR products were then separated on a T.A.E. agarose gel, stained with ethidium bromide, and examined for the correct size amplified band.
  • the pellet was then resuspended in 1 ml protoplast buffer, and Mutanolysin (Sigma Aldrich, St. Louis, Mo.) was then added at 5 U per ml of culture pelleted. The suspension was incubated overnight at room temperature. Cells were pelleted by centrifugation at 6000 rpm for 10 min, supernatant is stored at ⁇ 20° C. (Cell Wall Fraction). The protoplast were then washed in 1 ml of protoplast buffer. The formation of protoplasts was confirmed by microscopic examination. The protoplast were pelleted and lysed in 0.3-1 ml of dH 2 O, this is stored at ⁇ 20° C. (Cell Membrane/Cytosolic Fraction). Samples of each fraction are examined for the presence of PcpA by Western blot analysis.
  • Goat anti-rabbit immunoglobulin G (heavy and light chains)-alkaline phosphatase and streptavidin-alkaline phosphatase (Southern Biotechnology Associates, Inc., Birmingham, Ala.) were used as the secondary antibody. Colorimetric detection was performed with Sigma Fast nitrobluetetrazolium-5-bromo-4-chloro-3-indolylphosphate (NBT-BCIP) tablets (Sigma Aldrich, Switzerland).
  • CBA/N mice 6-8 week old CBA/CaHNBtkxid/J mice (JacksonLabs, Bar Harbor, Me.) were initially injected subcutaneously with 10 ⁇ g of rPcpA with 2 ⁇ g of Aluminum hydroxide as an adjuvant, 200 ⁇ l total volume. A second boost with 10 ⁇ g of rPcpA with Aluminum hydroxide was given 2 weeks later. A third boost containing 10 ⁇ g of rPcpA without Aluminum hydroxide was given 2 weeks following. The mice were then allowed to rest 2 weeks prior to challenge with S. pneumoniae . Mice were bled 24 hrs prior to infection.
  • Murine model of sepsis The virulence of pneumococci was examined in a systemic model of infection previously described (Coats, et al., Vaccine 23:4257-62 (2005); Ren et al., Infect. Immun. 71:75-85 (2003)). 6-8 week old CBA/N mice were injected intravenously with 300 CFUs of bacteria diluted in lactated ringers. Mice were monitored for 21 days. When they become unresponsive to touch and their body temperature decreased to below normal they were scored as moribund and the date and time were recorded. All moribund mice were euthanized with CO 2 narcosis.
  • Murine model of pneumonia Lung infections were performed as previously described (Balachandran et al., Infect. Immun. 70:2526-34 (2002); Briles et al., J. Infect. Dis. 188:339-48 (2003); Takashima et al., Infect. Immun. 65:257-260 (1997)).
  • 6-8 week old CBA/N mice were anesthetized with Isoflurane (MinRAD, Buffalo, N.Y.), and suspensions of 40 ⁇ l of lactated ringers solution containing 5 ⁇ 10 6 bacteria were introduced into the nares of the mice to induce aspiration pneumonia. After 7 days the mice were sacrificed.
  • mice The nasal cavities of sacrificed mice were washed with 50 ⁇ l of lactated ringers, as previously described (Wu et al., J Infect. Dis. 175:839-46 (997)).
  • the nasal wash was serially diluted and plated onto blood agar with gentamicin (4 ⁇ g/ml).
  • the lungs were harvested and placed into 2 ml of lactated ringers in a stomacher bag, homogenized, serially diluted, and plated onto blood agar with gentamicin in serial 3-fold dilutions.
  • Murine model of nasopharyngeal colonization Intranasal inoculations were performed as previously described (Balachandran et al., Infect. Immun. 70:2526-34 (2002); Wu et al., J. Infect. Dis. 175:839-46 (1997)). 6-8 week old CBA/N mice were infected intranasally with 10 6 bacteria in 10 ⁇ l of lactated Ringer's solution without anesthesia. Infected mice were then sacrificed, and their nasal cavities were washed with 50 ⁇ l of Ringer's solution. The nasal washes were serially diluted and plated on blood agar with gentamicin. Visible counts from blood agar plates were determined after overnight incubation at 37° C. in candle jars.
  • pcpA is present in clinically relevant strains of S. pneumoniae .
  • the presence of pcpA was examined by PCR, with primers (BGP1 and BGP2) spanning the LRR region of the pcpA.
  • BGP1 and BGP2 primers spanning the LRR region of the pcpA.
  • Each of the 23 strains examined yielded a roughly 1500-bp fragment.
  • Eight of these strains are clinical strains isolated within the last 25 years that are representative strains of the seven common capsular types covered by the 7-valent conjugate vaccine ( FIG. 1 ). The remaining 12 strains are a set of S.
  • pneumoniae that were selected from a set of strains assembled as part of the Genome Diversity Project (http://genome.microbio.uab.edu/strep/info/) which includes a set of strains chosen to span the breadth of diversity in S. pneumoniae .
  • These 12 strains were selected as highly divergent based on MLST data.
  • Four strains were from patients with serious invasive disease, five were from asymptomatic carriage, for 2 strains disease/colonization was not know, and one strain was from a worldwide antibiotic resistant clone.
  • These strains represent 12 different capsule types from different world regions.
  • PcpA is exposed on the surface of S. pneumoniae under low manganese conditions. Studies have shown that through the action of the regulator PsaR, manganese controls the transcription of the pcpA gene (Johnston et al., Infect. Immun. 74:1171-80 (2006)). As described herein, manganese dependent regulation directly affects the presence of PcpA on surface of S. pneumoniae and surface PcpA is accessible to antibody even on encapsulated pneumococci.
  • log-phase cells from wild type S. pneumoniae strain TIGR4 were grown in high or low manganese medium, stained with anti-PcpA polyclonal antiserum followed by fluorescein isothiocyanate (FITC)-conjugated anti-rabbit immunoglobulin.
  • TIGR4 was cultured in high or low Mn2+ medium until mid-log phase.
  • Bacteria were incubated with anti-PcpA rabbit serum, followed by incubation with FITC-conjugated anti-rabbit Ig antibodies.
  • Cells were then fixed in 4% formaldehyde containing the membrane dye TMA-DPH.
  • the labeled bacteria were then examined by immunofluorescence microscopy.
  • the antibodies to PcpA were able to mediate staining of the bacteria grown in low manganese, but not those grown in high manganese.
  • Immunization with rPcpA elicits antibody and provides protection against lung and systemic injection, but does not significantly affect nasopharyngeal colonization.
  • Mice were immunized with rPcpA with aluminum hydroxide or received aluminum hydroxide alone, prior to use in infection studies. Total Ig(H+L) was quantified for both groups of mice by ELISA.
  • the geometric mean level of antibody specific PcpA in the serum of the immunized mice was 0.465 ( ⁇ 0.119) ⁇ g/ml, versus a mean of 0.002 ( ⁇ 0.002) ⁇ g/ml for mice receiving the adjuvant alone, ( ⁇ SEM). This indicates the route of immunization was successful at eliciting an immune response to rPcpA.
  • PcpA and immunity to PcpA effects virulence in the murine model of systemic infection.
  • CBA/N mice were subcutaneously immunized with PcpA in aluminum hydroxide or aluminum hydroxide alone as a control and challenged intravenously with capsular type 4, TIGR4 S. pneumoniae .
  • This strain was used rather than EF3030 since this strain can readily cause bacteremia and sepsis in mice.
  • the immunized animals were injected IV with 300 CFU of TIGR4 strain S. pneumoniae . Survival was monitored for 21 days.
  • FIG. 8 mucosal immunization with PcpA protects against pulmonary infection with strain EF3030.
  • CBA/N mice were immunized intranasally with 5 ⁇ g of PcpA plus cholera toxin B sub-unit (CTB) as the adjuvant.
  • Post-immunization mice were bled and then challenged intranasally with 5 ⁇ 10 6 CFU of strain EF3030.
  • FIG. 8 shows log CFU of bacteria in lung homogenate at 7 days post-infection.
  • Mucosal immunization protection was observed to be slightly better than with immunization. These data and Example 1 indicate that protection against pneumonia and sepsis can be conferred using at least mucosal or subcutaneous routes of administration. Mucosal immunization with PcpA does not protect against nasal colonization with this strain. This is expected since PcpA is not expressed during colonization.
  • mice immunized with PcpA were examined for the level of antibody to PcpA.
  • CBA/N mice were immunized either subcutaneously (SC) with aluminum hydroxide or cholera toxin B subunit (CTB) as the adjuvant on days 0 and 14, and with PcpA alone on day 21.
  • SC subcutaneously
  • CTB cholera toxin B subunit
  • mice were bled and the antibody levels in the serum were determined by using as a standard the OD observed with a known concentrations of PspA antibodies reacting with PspA-coated microtitration plates.
  • additional groups of mice were immunized with diluent and adjuvant alone.
  • a 1.3-fold higher IgG antibody response was observed with SC rather than intranasal (IN) immunization (Table 5).
  • PcpA is Necessary for Adherence to Lung Cells
  • PcpA is necessary for adherence to the A549 cell line of transformed lung epithelial cells ( FIG. 9 ) but not to the Detroit562 line of transformed human nasal epithelial cell ( FIG. 10 ). It was observed that adherence to the A549 lung epithelial cells also required that the pneumococci be grown in low Mn 2+ so that they would produce PcpA.
  • the pneumococci for these studies were grown in Todd-Hewitt and Yeast medium (high Mn 2+ ) or Todd-Hewitt and Yeast Medium that had been passed over Chelex-100 (Sigma) and reconstituted with 0.1 ⁇ m MnSO 4 and 1 mM ZnCl 2 , MgCl 2 , CaCl 2 , and FeSO 4 . (low Mn 2+ ) (Briles et al., J. Infect. Dis. 188:339-48 (2003)). The Detroit 562 or A549 cells monolayers were incubated for 150 minutes with 10 6 CFU of TIGR4 (pcpA+) or JEN11 (pcpA ⁇ TIGR4 strain). The epithelial cells with adherent bacteria were washed and lysed with 0.5% Tween 20. The numbers of pneumococci in the lysate were determined by quantitative plating on blood agar plates.
  • Pneumolysin is another protein that can elicit some protection against lung infection (Briles et al., J. Infect. Dis. 188:339-48 (2003)). Since pneumolysin and PcpA are both candidates for use in protein-based pneumococcal vaccines, it was determined whether the two proteins produce better protection against lung infection when both are used as immunogens than when either one is used alone. Mice were immunized three times with 5 ⁇ g of PcpA, 5 ⁇ g pneumolysin, or 5 ⁇ g of PcpA plus 5 ⁇ g of pneumolysin. The first two injections were with alum and the third injections were with protein alone.
  • FIG. 13 shows that pneumolysin elicits similar protection against lung infection to that elicited by PcpA.
  • the combination of PcpA and pneumolysin was significantly more protective than pneumolysin alone.
  • strains in addition to those described in Examples 1-2 can be tested using the methods described above.
  • strains such as WU2, A66, BG7322, EF6796, D39 in addition to TIGR4 are tested. These strains are of capsular types 3, 3, 6B, 6A, and 2.
  • strains that work well in a mouse model of focal lung infection are used. These strains include EF9309, TG0893, L82016, BG7322 and EF6796. These are capsular types 23F, 14, 6B, 6B, and 6A.
  • a fragment of the pcpA gene from Streptococcus pneumoniae serotype 6 strain, 14453, ATCC Designation No. 55987 was cloned as follows.
  • the pcpA gene lacking the portion encoding the PcpA C-terminal choline-binding domain (CBD) repeats and lacking the portion encoding the native signal peptide (SP) sequence was cloned into pET-30a (Novagen, Inc., Madison, Wis.) between the NdeI and XhoI cloning sites as shown in FIG. 14 .
  • PCR polymerase chain reaction
  • the resulting 1335 base pair fragment encoding PcpA ⁇ SP ⁇ CBD contained the NdeI and XhoI sites at either end.
  • the amplified fragment was gel purified and digested with NdeI and XhoI, the pcpA gene fragment was then ligated between NdeI and XhoI sites of the pET-30a vector (Novagen, Inc., Madison, Wis.) with a strong T7 promoter and translation signals ( FIG. 14 ).
  • DNA sequencing confirmed that the recombinant plasmid pJMS87 contained the pcpA gene fragment ⁇ SP ⁇ CBD1335 bp.
  • Plasmid pJMS87 was transformed into the E. coli strain BL21 (DE3) for protein production. This E. coli strain upon induction with IPTG, expressed the PcpA protein lacking the native signal peptide ( ⁇ SP) and the c-terminal choline-binding domain ( ⁇ CBD). The expressed protein was identified by S
  • the sequence of the rPcpA protein (also known as PcpA ⁇ SP ⁇ CBD) is as follows.
  • the underlined residue (M) is from the cloning vector.
  • mice were immunized with 10, 5, 2.5, 1.25, and 0.625 ⁇ g per dose of purified recombinant PcpA ⁇ SP ⁇ CBD (rPcpA ⁇ SP ⁇ CBD) and challenged with approximately 300 CFU of S. pneumoniae strain WUBM3 per mouse.
  • the rPcpA ⁇ SP ⁇ CBD was formulated with aluminum phosphate adjuvant.
  • mice were immunized with a PBS adjuvant control, S. pneumoniae PspA protein containing 30 ⁇ g of trivalent recombinant PspA protein, or 10, 5, 2.5, 1.25, or 0.625 ⁇ g per dose rPcpA ⁇ SP ⁇ CBD.
  • Healthy female BALB/c K-72 mice (Charles River Laboratories, Wilmington, Mass.), approximately 14 per group, were immunized at day 0 subcutaneously (s.c.). A second immunization was performed at day 21 and a third immunization at day 43.
  • the mice were challenged intraperitoneally (IP) with a 0.4 ml dose of about 300 CFU of S. pneumoniae strain WU2BM3 bacteria.
  • IP intraperitoneally
  • the percent survival plotted against time (days) is shown in FIG. 15A .
  • the percent survival at day 7 post challenge is shown in FIG. 15B .
  • rPcpA is protective from at least about 0.625 ⁇ g per dose to at least about 10 ⁇ g per dose.
  • a statistically significant protection was conferred by rPcpA compared to the adjuvant control group (Fisher Exact Test 1-sided or 2-sided).
  • the rPcpA protein of Example 5 was also used to test the protective efficacy of this protein against challenge with S. pneumoniae strain EF3030 in a mouse pneumonia model.
  • Groups of 10 CBA/N mice were immunized subcutaneously with 200 ⁇ l of an immunogen formulation as shown in Table 7, three (3) times at 3 week intervals (day 0, 21 and 42).
  • Three weeks post the 3 rd immunization (day 63), the mice were challenged, under anesthesia, intranasally with 5.6 ⁇ 10 6 CFUs of strain EF3030.
  • the immunization groups were formulated in aluminum phosphate adjuvant at 3 mg/ml.
  • Group Immunogen formulation 1 Placebo (3 mg/mL AlPO 4 ) 2 Trivalent PspA (50 ⁇ g/mL each + 3 mg/mL AlPO 4 ) 3 PcpA - (100 ⁇ g/mL + 3 mg/mL AlPO 4 ) 4 PcpA - (50 ⁇ g/mL + 3 mg/mL AlPO 4 ) 5 PcpA - (25 ⁇ g/mL + 3 mg/mL AlPO 4 ) 6 PcpA - (12.5 ⁇ g/mL + 3 mg/mL AlPO 4 ) Trivalent PspA immunogen consisted of PspA from S. pneumoniae Rx1-M1, EF3296 and EF5668.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
US12/377,446 2006-08-17 2007-08-17 Immunogenic PcpA Polypeptides and Uses Thereof Abandoned US20110002962A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/377,446 US20110002962A1 (en) 2006-08-17 2007-08-17 Immunogenic PcpA Polypeptides and Uses Thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82271506P 2006-08-17 2006-08-17
US82734806P 2006-09-28 2006-09-28
US91717807P 2007-05-10 2007-05-10
US12/377,446 US20110002962A1 (en) 2006-08-17 2007-08-17 Immunogenic PcpA Polypeptides and Uses Thereof
PCT/US2007/076180 WO2008022302A2 (fr) 2006-08-17 2007-08-17 polypeptides immunogéniques de PCPA et leurs utilisations

Publications (1)

Publication Number Publication Date
US20110002962A1 true US20110002962A1 (en) 2011-01-06

Family

ID=38942273

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/377,440 Active 2028-10-24 US8252546B2 (en) 2006-08-17 2007-08-17 Diagnosing pneumococcal pneumonia
US12/377,446 Abandoned US20110002962A1 (en) 2006-08-17 2007-08-17 Immunogenic PcpA Polypeptides and Uses Thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/377,440 Active 2028-10-24 US8252546B2 (en) 2006-08-17 2007-08-17 Diagnosing pneumococcal pneumonia

Country Status (11)

Country Link
US (2) US8252546B2 (fr)
EP (2) EP2081953A2 (fr)
JP (3) JP5081243B2 (fr)
KR (1) KR101523108B1 (fr)
CN (2) CN101573374A (fr)
AU (1) AU2007285775B2 (fr)
BR (1) BRPI0715975A2 (fr)
CA (2) CA2660743C (fr)
IL (1) IL197094A (fr)
MX (1) MX2009001778A (fr)
WO (3) WO2008022298A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649372B2 (en) 2009-12-22 2017-05-16 Sanofi Pasteur Limited Immunogenic compositions and related methods
US20180296660A1 (en) * 2014-10-31 2018-10-18 Cansino Biologics Inc. Immunogenic composition for preventing pneumococcal diseases and preparation method thereof

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
EP2081953A2 (fr) * 2006-08-17 2009-07-29 The UAB Research Foundation Polypeptides immunogeniques de pcpa e leur utilisations
CA2721129A1 (fr) * 2007-04-12 2008-10-23 Carolyn Marie Slupsky Detection urinaire d'un etat pathologique provoque par une infection a pneumocoque
BRPI0907010A2 (pt) * 2008-02-01 2015-07-07 Sanofi Pasteur Ltd Análise para o diagnóstico de streptococcus pneumoniae
EA201001479A1 (ru) * 2008-04-16 2011-06-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
WO2009143483A2 (fr) * 2008-05-22 2009-11-26 The Board Of Regents Of The University Of Texas System Le psrp est un antigène protecteur contre une infection pneumococcique
KR101741426B1 (ko) * 2008-12-24 2017-05-30 더 킹덤 오드 더 네덜란드, 레프리젠티드 바이 더 미니스트리 오브 헬스, 웰페어 앤드 스포츠, 온 비하프 오브 더 미니스터, 더 내셔널 인스티튜트 포 퍼블릭 헬스 앤드 디 인바이런먼트 변형된 스트렙토코커스 뉴모니아 뉴몰리신(ｐｌｙ) 폴리펩타이드
JP5204036B2 (ja) * 2009-05-28 2013-06-05 旭化成株式会社 肺炎球菌の検出方法
EP2515938A4 (fr) 2009-12-22 2013-08-28 Sanofi Pasteur Ltd Compositions immunogènes
US20110262989A1 (en) * 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
CA2819758A1 (fr) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition pour l'immunisation contre streptococcus pneumoniae
US8603769B2 (en) * 2011-10-07 2013-12-10 Becton, Dickinson And Company Method for direct and rapid identification of microorganisms and antimicrobial susceptibility testing from positive blood cultures
CA2865582C (fr) 2012-02-29 2021-03-16 Becton, Dickinson And Company Formulations et methode pour isoler des micro-organismes viables a partir d'hemocultures positives
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
PL3383376T3 (pl) * 2015-12-01 2021-10-04 The Procter & Gamble Company Sposoby hamowania przemiany choliny w trimetyloaminę (tma)
JP6770805B2 (ja) * 2016-01-28 2020-10-21 旭化成株式会社 検体中の特定の細菌を検出する方法
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN106636149B (zh) * 2017-01-03 2019-10-25 内蒙古农业大学 斯氏副柔线虫丝氨酸/苏氨酸蛋白激酶Pj_STPK基因克隆、原核表达方法及应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110387427A (zh) * 2018-04-16 2019-10-29 马东礼 用于检测肺炎链球菌的引物组及试剂盒

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US5792457A (en) * 1991-05-03 1998-08-11 The Rockefeller University Antibody recognizing endothelial cell ligand for leukocyte CR3
US6027734A (en) * 1991-02-15 2000-02-22 Uab Research Foundation Mucosal administration of pneumococcal antigens
US6217884B1 (en) * 1991-11-14 2001-04-17 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-kDa surface adhesin a protein
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US6312944B1 (en) * 1991-11-14 2001-11-06 The United States Of America As Represented By The Department Of Health And Human Services Pneumococcal fimbrial protein A
US6500613B1 (en) * 1995-09-15 2002-12-31 University Of Alabama At Birmingham Pneumococcal surface proteins and uses thereof
US6514503B1 (en) * 1997-07-09 2003-02-04 Lyfjathoun Hf Antigen delivery system
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6573082B1 (en) * 1996-10-31 2003-06-03 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
US6635246B1 (en) * 1999-02-11 2003-10-21 Baxter Healthcare S.A. Inactivated influenza virus vaccine for nasal or oral application
US6699703B1 (en) * 1997-07-02 2004-03-02 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US20040110181A1 (en) * 2001-04-16 2004-06-10 Zagursky Robert John Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US20050020813A1 (en) * 2001-03-27 2005-01-27 Vega Masignani Streptococcus pneumoniae proteins and nucleic acids
US20060051361A1 (en) * 2000-09-15 2006-03-09 Laferriere Craig A J Vaccine against Streptococcus pneumoniae
US20060263846A1 (en) * 2003-04-15 2006-11-23 Intercell Ag S. penumoniae antigens
US20060264378A1 (en) * 2002-08-27 2006-11-23 Takeda Pharmaceutical Company Limited Cxcr4 antagonist and use thereof
US7202056B2 (en) * 2002-03-28 2007-04-10 Bristol-Myers Squibb Company Polynucleotides encoding a human cell surface protein with immunoglobulin folds, BGS-19
WO2008022299A1 (fr) * 2006-08-17 2008-02-21 The Uab Research Foundation Diagnostic d'une pneumonie à pneumocoques
US20080085277A1 (en) * 2004-06-18 2008-04-10 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20090010959A1 (en) * 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
US20110130300A1 (en) * 2008-02-01 2011-06-02 Martina Ochs-Onolemhemhen Assay for diagnosing streptococcus pneumoniae
US20140017274A1 (en) * 2011-03-23 2014-01-16 Immunobiology Limited Method for the production of protein complexes and vaccine compositions comprising the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361365T1 (de) 1998-07-27 2007-05-15 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
MXPA01012721A (es) * 1999-06-10 2004-10-14 Uab Research Foundation Vacuna de combinacion de proteinas de superficie neumococcicas.
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
JP2007512006A (ja) * 2003-11-10 2007-05-17 ザ ユーエービー リサーチ ファウンデーション 細菌輸送およびｃｎｓ侵襲を低減させるための組成物およびこの組成物を使用する方法

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US6027734A (en) * 1991-02-15 2000-02-22 Uab Research Foundation Mucosal administration of pneumococcal antigens
US5792457A (en) * 1991-05-03 1998-08-11 The Rockefeller University Antibody recognizing endothelial cell ligand for leukocyte CR3
US6217884B1 (en) * 1991-11-14 2001-04-17 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-kDa surface adhesin a protein
US6312944B1 (en) * 1991-11-14 2001-11-06 The United States Of America As Represented By The Department Of Health And Human Services Pneumococcal fimbrial protein A
US6592876B1 (en) * 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US6500613B1 (en) * 1995-09-15 2002-12-31 University Of Alabama At Birmingham Pneumococcal surface proteins and uses thereof
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US6784164B2 (en) * 1996-05-01 2004-08-31 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US6573082B1 (en) * 1996-10-31 2003-06-03 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
US6699703B1 (en) * 1997-07-02 2004-03-02 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US6514503B1 (en) * 1997-07-09 2003-02-04 Lyfjathoun Hf Antigen delivery system
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6635246B1 (en) * 1999-02-11 2003-10-21 Baxter Healthcare S.A. Inactivated influenza virus vaccine for nasal or oral application
US20060051361A1 (en) * 2000-09-15 2006-03-09 Laferriere Craig A J Vaccine against Streptococcus pneumoniae
US20050020813A1 (en) * 2001-03-27 2005-01-27 Vega Masignani Streptococcus pneumoniae proteins and nucleic acids
US20040110181A1 (en) * 2001-04-16 2004-06-10 Zagursky Robert John Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US7384775B2 (en) * 2001-04-16 2008-06-10 Wyeth Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US7202056B2 (en) * 2002-03-28 2007-04-10 Bristol-Myers Squibb Company Polynucleotides encoding a human cell surface protein with immunoglobulin folds, BGS-19
US20060264378A1 (en) * 2002-08-27 2006-11-23 Takeda Pharmaceutical Company Limited Cxcr4 antagonist and use thereof
US20060263846A1 (en) * 2003-04-15 2006-11-23 Intercell Ag S. penumoniae antigens
US7635487B2 (en) * 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
US20080085277A1 (en) * 2004-06-18 2008-04-10 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20090010959A1 (en) * 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
WO2008022299A1 (fr) * 2006-08-17 2008-02-21 The Uab Research Foundation Diagnostic d'une pneumonie à pneumocoques
US20110130300A1 (en) * 2008-02-01 2011-06-02 Martina Ochs-Onolemhemhen Assay for diagnosing streptococcus pneumoniae
US20140017274A1 (en) * 2011-03-23 2014-01-16 Immunobiology Limited Method for the production of protein complexes and vaccine compositions comprising the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Houghten et al. New Approaches to Immunization, Vaccines86, Cold Spring Harbor Laboratory, pages 21-25, 1986 *
Lazar et al. Mol. Cellular Biol. 8: 1247-1252, 1988 *
Rudinger J. In: Peptide Hormones. (Ed) JA Parsons, University Park Press, pages 1-7, 1976 *
Skolnick et al. Trends in Biotechnology 18: 34-39, 2000 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649372B2 (en) 2009-12-22 2017-05-16 Sanofi Pasteur Limited Immunogenic compositions and related methods
US20180296660A1 (en) * 2014-10-31 2018-10-18 Cansino Biologics Inc. Immunogenic composition for preventing pneumococcal diseases and preparation method thereof
US10376572B2 (en) * 2014-10-31 2019-08-13 Cansino Biologics Inc. Immunogenic composition for preventing pneumococcal diseases and preparation method thereof

Also Published As

Publication number Publication date
JP2010501078A (ja) 2010-01-14
BRPI0715975A2 (pt) 2014-03-18
MX2009001778A (es) 2009-05-22
WO2008022302A3 (fr) 2008-04-03
EP2081953A2 (fr) 2009-07-29
CA2660743C (fr) 2015-11-24
IL197094A (en) 2014-12-31
CN101573374A (zh) 2009-11-04
KR101523108B1 (ko) 2015-05-26
EP2059807A1 (fr) 2009-05-20
JP5081243B2 (ja) 2012-11-28
WO2008022299A1 (fr) 2008-02-21
JP2013155205A (ja) 2013-08-15
WO2008022302A2 (fr) 2008-02-21
EP2059807A4 (fr) 2010-01-27
CA2661210A1 (fr) 2008-02-21
JP2010501012A (ja) 2010-01-14
US20100227341A1 (en) 2010-09-09
CN107056902A (zh) 2017-08-18
US8252546B2 (en) 2012-08-28
IL197094A0 (en) 2011-08-01
JP5932711B2 (ja) 2016-06-08
CA2660743A1 (fr) 2008-02-21
AU2007285775B2 (en) 2011-03-03
WO2008022298A3 (fr) 2008-04-03
EP2059807B1 (fr) 2013-02-20
WO2008022298A2 (fr) 2008-02-21
AU2007285775A1 (en) 2008-02-21
KR20090071551A (ko) 2009-07-01

Similar Documents

Publication Publication Date Title
CA2660743C (fr) Polypeptides immunogeniques de pcpa et leurs utilisations
EP1141306B1 (fr) Antigenes de streptococcus
US7927608B2 (en) Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications
NZ553554A (en) Streptococcus antigens
AU2001270381A1 (en) Streptococcus antigens
US20060177465A1 (en) Streptococcus antigens
EP2266591A2 (fr) Protéines protectrices de S. agalactia, combinaisons associées et procédés d'utilisation
JP2005535287A (ja) グループｂ連鎖球菌抗原
AU2011202678B2 (en) Immunogenic PcpA polypeptides and uses thereof
AU2013200079A1 (en) Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications
CZ148399A3 (cs) Sekvence nukleových kyselin a aminokyselin Helicobacter pylori a vakcinační prostředky

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI PASTEUR LTD., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YETHON, JEREMY;WANG, JOE;SIGNING DATES FROM 20080421 TO 20080423;REEL/FRAME:020981/0111

AS Assignment

Owner name: THE UAB RESEARCH FOUNDATION, ALABAMA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRILES, DAVID E.;HOLLINGSHEAD, SUSAN K.;REEL/FRAME:025056/0229

Effective date: 20070618

Owner name: SANOFI PASTEUR LTD., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YETHON, JEREMY;WANG, JOE;SIGNING DATES FROM 20080421 TO 20080423;REEL/FRAME:025056/0238

AS Assignment

Owner name: THE UAB RESEARCH FOUNDATION, ALABAMA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRILES, DAVID E.;HOLLINGSHEAD, SUSAN K.;REEL/FRAME:029851/0211

Effective date: 20070618

AS Assignment

Owner name: SANOFI PASTEUR LTD., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YETHON, JEREMY;WANG, JOE;SIGNING DATES FROM 20080421 TO 20080423;REEL/FRAME:029857/0563

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ALABAMA AT BIRMINGHAM;REEL/FRAME:051482/0446

Effective date: 20200108

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ALABAMA AT BIRMINGHAM;REEL/FRAME:054474/0932

Effective date: 20190103

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ALABAMA AT BIRMINGHAM;REEL/FRAME:055637/0124

Effective date: 20190103